Inhibitory effect of troglitazone on diabetic neuropathy in streptozotocin-induced diabetic rats

Diabetologia

Volumn 41, Issue 11, 1998, Pages 1321-1326

  Qiang, X ^a   Satoh, J ^a   Sagara, M ^a   Fukuzawa, M ^a   Masuda, T ^b   Sakata, Y ^a   Muto, G ^a   Muto, Y ^a   Takahashi, K ^a   Toyota, T ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

Author keywords

Diabetic neuropathy; Free radical scavenger; Motor nerve conduction velocity (MNCV); Troglitazone; Tumour necrosis factor (TNF )

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLUCOSE; INSULIN; LIPID PEROXIDE; LIPOPOLYSACCHARIDE; SCAVENGER; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEUROPATHY; DRUG EFFECT; MALE; MOTOR NERVE; MYELINATION; NERVE CONDUCTION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES; TIBIAL NERVE;

ANIMALS; ANTIOXIDANTS; BLOOD GLUCOSE; BODY WEIGHT; CHROMANS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; LIPID PEROXIDATION; LIPID PEROXIDES; MALE; MOTOR NEURONS; NEURAL CONDUCTION; RATS; RATS, WISTAR; THIAZOLES; THIAZOLIDINEDIONES; TIBIAL NERVE;

EID: 15444342189     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250051072     Document Type: Article

References (25)

1. Cameron NE, Cotter MA, Basso M, Hohman TC (1997) Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia 40: 271-281
2. Gries AF (1995) Alternative therapeutic principles in the prevention of microvascular and neuropathic complications. Diabetes Res Clin Pract 28: 201-207
3. Tanaka S, Seino H, Satoh J et al. (1992) Increased in vivo production of tumour necrosis factor after development of diabetes in nontreated, long-term diabetic BB rats. Clin Immunol Immunopathol 62: 258-263
4. Sagara M, Satoh J, Zhu XP et al. (1994) Inhibition with N-acetylcysteine of enhanced production of tumour necrosis factor in streptoxotocin-induced diabetic rats. Clin Immunol Immunopathol 71: 333-337
5. Nishimura S, Satoh J, Toyota T (1997) Serum TNF-α levels and diabetic complications in NIDDM patients. Diabetologia 40 [Suppl 1]:A601
6. Sagara M, Satoh J, Wada R et al. (1996) Inhibition of development of peripheral neuropathy in streptozotocin-induced diabetic rats with N-acetylcysteine. Diabetologia 39: 263-269
7. Qiang X, Satoh J, Sagara M et al. (1995) Treatment of diabetic neuropathy with pentoxifylline. J Jpn Diabete Soc 38 [Suppl]:378
8. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 270: 12953-12956
9. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I et al. (1988) Characterization of new oral antidiabetic agent troglitazone. Diabetes 37: 1549-1558
10. Iwamoto Y, Kuzuya T, Matsuda A et al. (1991) Effects of new oral hypoglycemic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care 14: 1083-1086
11. Scott NA, Jennings PE, Brown J et al. (1991) Troglitazone: a general free radical scavenger. Eur J Pharmacol 208: 175-177
12. Jennings PE, Scott NA, Saniabadi AR et al. (1992) Effects of troglitazone on platelet reactivity and free radicals in type II diabetic patients: clinical assessment. Metabolism 41: 36-39
13. Noguchi N, Sakai H, Kato Y et al. (1996) Inhibition of oxidation of low density lipoprotein by troglitazone. Atherosclerosis 123: 227-234
14. Ohsumi J, Sakakibara S, Yamaguchi J et al. (1994) Troglitazone prevents the inhibitory effects of inflammatory cytokines on insulin-induced adipocyte differentiation in 3T3-L1 cells. Endocrinology 135: 2279-2282
15. Szalkowski D, White-Carrington S, Berger J, Shang B (1995) Antidiabetic thiazolidinediones block the inhibitory effect of tumour necrosis factor-α on differentiation, insulin-stimulated glucose uptake, and gene expression in 3T3-L1 cells. Endocrinology 136: 1474-1481
16. Yagihashi S, Kamijo M, Ido Y, Mirrlees DJ (1990) Effects of long-term aldose reductase inhibition on development of experimental diabetic neuropathy. Diabetes 39: 690-696
17. Yagi K (1976) A simple fluorometric assay for lipoperoxide in blood plasma. Biochemical Medicine 15: 212-216
18. Satoh J, Seino H, Abo T et al. (1989) Recombinant human tumour necrosis factor-α suppresses autoimmune diabetes in nonobese diabetic mice. J Clin Invest 84: 1345-1348
19. Sima AAF, Brown MB, Prashar A, Chakrabarti S, Laudadio C, Greene DA (1992) The reproducibility and sensitivity of sural nerve morphometry in the assessment of diabetic peripheral polyneuropathy. Diabetologia 35: 560-569
20. Cotter MA, Love A, Watt MJ, Cameron NE, Dines KC (1995) Effects of natural free radical scavengers on peripheral nerve and neurovascular function in diabetic rats. Diabetologia 38: 1285-1294
21. Low PA, Nickander KK, Tritschler HJ (1997) The roles of oxidative stress and antioxidant treatment in experimental diabetic neuropathy. Diabetes 46 [Suppl 2]:S38-S42
22. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK (1998) The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391: 79-82
23. Jiang C, Ting AT, Seed B (1998) PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 391: 82-86
24. Langenstroer P, Pieper GM (1992) Regulation of spontaneous EDRF release in diabetic rat aorta by oxygen free radicals. Am J Physiol 263: H257-H265
25. Dawson DA, Martin D, Hallenbeck JM (1996) Inhibition of tumour necrosis factor-alpha reduces focal cerebral ischemic injury in the spontaneously hypertensive rat. Neurosci Lett 218: 41-44